Closing the gap: A United States perspective on enhancing drug evaluation in older adults

Author:

Lau S. W. Johnny1,Liu Qi1,Madabushi Rajanikanth1,Temple Robert2

Affiliation:

1. Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA

2. Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA

Publisher

Wiley

Reference15 articles.

1. Issue Information

2. Code of Federal Regulation Title 21 Part 314 Section 50 of the 4‐1‐86 Edition.

3. US FDA Final Rule.63 FR 6854. 21 CFR 312 and 21 CFR 314: investigational new drug applications and new drug applications. (Demographic Rule) Federal Register 1998;63:6854–6862.

4. GUIDANCE DOCUMENT: format and content of the clinical and statistical sections of an application. US FDA. Accessed February 20 2024.https://www.fda.gov/media/71436/download

5. US Government.PUBLIC LAW 112–144—JULY 9 2012. Accessed February 20 2024.https://www.congress.gov/112/plaws/publ144/PLAW-112publ144.pdf

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3